THE BASIC PRINCIPLES OF SELINEXOR (KPT-330)

The security and efficacy of erlotinib have not been proven for patients with NSCLC whose tumors clearly show other EGFR mutations. On top of that it is not proposed for use together with platinum-centered chemotherapy. LabelUncomfortable side effects that usually don't involve professional medical consideration (report back to your medical doctor